Target intelligence / Profile preview

Histone demethylase UTY (UTY)

Target
UTY
Molecular classification
Enzyme, Histone demethylase, Chromatin-modifying enzyme
01

Overview

Histone demethylase UTY is a Y-chromosome-encoded enzyme in humans responsible for catalyzing the demethylation of trimethylated lysine 27 on histone H3 (H3K27me3), although it has significantly lower catalytic activity compared to its X chromosome homolog KDM6A (UTX)[4][5]. UTY contains tetratricopeptide repeat domains implicated in protein–protein interactions and plays a role in chromatin organization and epigenetic gene regulation. It is male-specific and also functions as a minor histocompatibility antigen, which can trigger immune responses leading to graft rejection in male-to-female stem cell transplantation[3]. While it is enzymatically active in vitro, its activity is lower and possibly more target-selective in cells compared to KDM6A[4][5]. Emerging studies indicate UTY may also contribute to gene regulation via demethylase-independent mechanisms[1]. Its dysfunction or misregulation has been implicated in developmental anomalies and cancer, and its antigenicity is clinically notable in transplantation settings[1][3][4].

Other names
KDM6CKDM6ALUbiquitously transcribed tetratricopeptide repeat protein on the Y chromosomeUbiquitously transcribed TPR gene on Y chromosomeUbiquitously transcribed tetratricopeptide repeat gene, Y-linkedUbiquitous TPR motif protein UTYMinor histocompatibility antigen UTY[Histone H3]-trimethyl-L-lysine(27) demethylase UTY
02

Mechanism of action

Inhibition of UTY would be expected to increase histone H3K27 methylation, promoting transcriptional repression at specific loci[4][5].

03

Biological functions

Epigenetic regulationTranscriptional regulationProtein–protein interactions
04

Disease associations

CancerMinor histocompatibility antigen (graft rejection)Developmental disorders
05

Safety considerations

Potential for altered gene expression impacting development, cell fate, or immune recognition, given its role in embryonic development and as a minor histocompatibility antigen[1][3].
06

Interacting drugs

None with established, clinically approved direct targeting as of current evidence
07

Biomarkers

Minor histocompatibility antigen (in the context of Y chromosome stem cell grafts)[3]H3K27 methylation status (as indirect readout in systems with high UTY activity)[4][5]

Beyond the preview

Go deeper on Histone demethylase UTY (UTY).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone demethylase UTY (UTY).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call